Seeking Alpha

Ziopharm Oncology gets approval for brain cancer study

  • Ziopharm Oncology (ZIOP) gets approval from the RAC to run a Phase 1 study of Ad-RTS-IL-12 in brain cancer.
  • The company expects to launch the study in H1 of next year.
  • Ad-RTS-IL-12 is in Phase 2 testing for melanoma and breast cancer. (PR)
  • Reminder: Ad-RTS-IL-12 is developed with a controlled expression platform from Intrexon (XON).
  • ZIOP +10.3% premarket
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: